This company listing is no longer active
0Y5F Stock Overview
A specialty pharmaceutical company, develops, manufactures, markets, and sells various pharmaceutical products in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Endo International plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.0006 |
| 52 Week High | €0.069 |
| 52 Week Low | €0.0003 |
| Beta | 0.80 |
| 1 Month Change | 100.00% |
| 3 Month Change | 0% |
| 1 Year Change | -98.97% |
| 3 Year Change | -99.99% |
| 5 Year Change | -99.99% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0Y5F | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | 0.3% | 0.9% |
| 1Y | -99.0% | -12.6% | 0.7% |
Return vs Industry: 0Y5F underperformed the UK Pharmaceuticals industry which returned 6.3% over the past year.
Return vs Market: 0Y5F underperformed the UK Market which returned 3.5% over the past year.
Price Volatility
| 0Y5F volatility | |
|---|---|
| 0Y5F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in GB Market | 11.2% |
| 10% least volatile stocks in GB Market | 3.2% |
Stable Share Price: 0Y5F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0Y5F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 2,931 | Blaise Coleman | www.endo.com |
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company offers branded pharmaceuticals, including XIAFLEX to treat adult patients with Dupuytren’s contracture and Peyronie’s disease; SUPPRELIN LA to treat central precocious puberty in children; AVEED to treat hypogonadism; NASCOBAL nasal spray to treat vitamin B12 deficiency; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET for pain management; TESTOPEL, an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; and EDEX to treat erectile dysfunction, as well as opioid products to treat pain associated with post-herpetic neuralgia.
Endo International plc Fundamentals Summary
| 0Y5F fundamental statistics | |
|---|---|
| Market cap | US$151.59k |
| Earnings (TTM) | -US$2.45b |
| Revenue (TTM) | US$2.01b |
0.0x
P/S Ratio0.0x
P/E RatioIs 0Y5F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0Y5F income statement (TTM) | |
|---|---|
| Revenue | US$2.01b |
| Cost of Revenue | US$941.90m |
| Gross Profit | US$1.07b |
| Other Expenses | US$3.52b |
| Earnings | -US$2.45b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -10.41 |
| Gross Margin | 53.17% |
| Net Profit Margin | -121.69% |
| Debt/Equity Ratio | -123.5% |
How did 0Y5F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/03 19:23 |
| End of Day Share Price | 2024/05/03 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Endo Inc. is covered by 45 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Richard Silver | Barclays |
| Gary Nachman | BMO Capital Markets Equity Research |
| Sumant Satchidanand Kulkarni | BofA Global Research |